Daniel Devine & Co’s AstraZeneca AZN Stock Holding History

Daniel Devine & Co’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	$506K	Sell	7,200 -11,500	-61%	-$827K	0.4%	38
2018 Q1	$1.31M	Hold	18,700	–	–	1.06%	27
2017 Q4	$1.3M	Hold	18,700	–	–	0.94%	25
2017 Q3	$1.27M	Hold	18,700	–	–	0.97%	26
2017 Q2	$1.27M	Sell	18,700 -2,650	-12%	-$173K	1.04%	23
2017 Q1	$1.33M	Hold	21,350	–	–	1.09%	24
2016 Q4	$1.17M	Hold	21,350	–	–	0.83%	31
2016 Q3	$1.4M	Hold	21,350	–	–	0.94%	30
2016 Q2	$1.29M	Hold	21,350	–	–	0.88%	34
2016 Q1	$1.2M	Buy	21,350 +17,650	+477%	+$1.06M	0.78%	41
2015 Q4	$251K	Hold	3,700	–	–	0.17%	63
2015 Q3	$235K	Hold	3,700	–	–	0.17%	61
2015 Q2	$236K	Hold	3,700	–	–	0.16%	58
2015 Q1	$253K	Buy	+3,700	New	+$257K	0.17%	59

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Daniel Devine & Co's AZN Position: Q2 2018 in Review

Daniel Devine & Co reduced its AstraZeneca (AZN) stake by 61% in Q2 2018, selling an estimated $827K and leaving 7,200 shares worth $506K. The position accounts for 0.4% of the portfolio, ranked #38.

Daniel Devine & Co first reported a position in AZN in Q1 2015 and has held it in 14 quarters since. The position peaked at $1.4M in Q3 2016. 531 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

Daniel Devine & Co held 7,200 shares of AstraZeneca worth $506K as of Q2 2018.
Daniel Devine & Co sold 11,500 AstraZeneca shares in Q2 2018, an estimated $827K.
AstraZeneca made up 0.4% of Daniel Devine & Co's portfolio in Q2 2018, its #38 holding.
Daniel Devine & Co first reported a position in AstraZeneca in Q1 2015 and has held it in 14 quarters since.
Daniel Devine & Co's AstraZeneca position peaked at $1.4M in Q3 2016.
531 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on Daniel Devine & Co's 13F filing for Q2 2018, filed 18 Jul 2018.